Clinical efficacy of Mac-2-binding protein glycosylation isomer as a biomarker for albumin-bilirubin grade and the Controlling Nutritional Status score in chronic liver disease: investigation of cut-off values by the type of chronic liver disease | Zendy

Toru Ishikawa | Zendy; Erina Kodama | Zendy; Takamasa Kobayashi | Zendy; Motoi Azumi | Zendy; Yujiro Nozawa | Zendy; Akito Iwanaga | Zendy; Tomoe Sano | Zendy; Terasu Honma | Zendy

Open Access

Clinical efficacy of Mac-2-binding protein glycosylation isomer as a biomarker for albumin-bilirubin grade and the Controlling Nutritional Status score in chronic liver disease: investigation of cut-off values by the type of chronic liver disease

Author(s) -

Toru Ishikawa,

Erina Kodama,

Takamasa Kobayashi,

Motoi Azumi,

Yujiro Nozawa,

Akito Iwanaga,

Tomoe Sano,

Terasu Honma

Publication year - 2022

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-22-270

Subject(s) - medicine , biomarker , albumin , bilirubin , glycosylation , chronic liver disease , gastroenterology , disease , liver disease , biochemistry , cirrhosis , chemistry

Mac-2-binding protein glycosylation isomer (M2BPGi), a novel noninvasive biomarker for fibrosis, is a prognostic factor for liver disease; however, its relationship with hepatic function reserve and nutritional status remains unclear. Furthermore, the cut-off value of this marker varies with the underlying liver disease. This study aims to clarify that M2BPGi can be clinically used as a hepatic function reserve marker and nutritional index without pushing the search for alternative markers to the forefront in clinical practice as an important biomarker.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research